Home
Videos
Dermbits
Hair Recoverable In Pattern Hair Loss

#top-leaderboard-ads, .stickyads { position: static !important; }

Is hair recoverable in pattern hair loss?

Featuring:

AMAmy McMichael, MDFaculty

Updated:Apr 28, 2023

What characteristics of a localized inflammatory lesion make you more likely to consider Cordran Tape, and what have those cases taught you about the value of occlusion?

What characteristics of a localized inflammatory lesion make you more likely to consider Cordran Tape, and what have those cases taught you about the value of occlusion?

In patients with chronic hand eczema and fissuring, what clinical or lifestyle factors make you consider Cordran Tape, and what have you observed in those cases?

In patients with chronic hand eczema and fissuring, what clinical or lifestyle factors make you consider Cordran Tape, and what have you observed in those cases?

When treating patients whose disease is being perpetuated by scratching, rubbing, or picking, what advantages have you found Cordran Tape can offer beyond topical steroid delivery alone?

When treating patients whose disease is being perpetuated by scratching, rubbing, or picking, what advantages have you found Cordran Tape can offer beyond topical steroid delivery alone?

How often do real-world lifestyle factors influence your treatment selection in localized inflammatory skin disease, and are there situations where Cordran Tape has helped address challenges that traditional topical regimens could not?

How often do real-world lifestyle factors influence your treatment selection in localized inflammatory skin disease, and are there situations where Cordran Tape has helped address challenges that traditional topical regimens could not?

In inflammatory dermatoses, are there situations where changing the treatment strategy is more important than simply choosing a stronger medication?

In inflammatory dermatoses, are there situations where changing the treatment strategy is more important than simply choosing a stronger medication?

How often do factors such as scratching, friction, repetitive trauma, or occupational exposure contribute to treatment resistance in dermatology?

How often do factors such as scratching, friction, repetitive trauma, or occupational exposure contribute to treatment resistance in dermatology?

What types of psoriasis patients tend to fall into a treatment “gray zone,” and where has apremilast fit into your approach for those individuals?

What types of psoriasis patients tend to fall into a treatment “gray zone,” and where has apremilast fit into your approach for those individuals?

How do you set treatment goals with apremilast differently than you might with other systemic therapies?

How do you set treatment goals with apremilast differently than you might with other systemic therapies?

What have you learned about managing patients who improve on apremilast but do not achieve the level of response they initially hoped for?

What have you learned about managing patients who improve on apremilast but do not achieve the level of response they initially hoped for?

What factors most strongly influence whether patients feel successful on apremilast?

What factors most strongly influence whether patients feel successful on apremilast?

How do you approach psoriasis treatment decisions when objective measures and patient perception of disease severity do not align?

How do you approach psoriasis treatment decisions when objective measures and patient perception of disease severity do not align?

What challenges arise when treatment expectations are shaped by increasingly effective therapies for psoriasis?

What challenges arise when treatment expectations are shaped by increasingly effective therapies for psoriasis?

What do you do when coverage lags behind innovation?

What do you do when coverage lags behind innovation?

When does combination therapy complicate access—and how do you navigate it?

When does combination therapy complicate access—and how do you navigate it?

How do you manage access for patients with limited follow-up reliability?

How do you manage access for patients with limited follow-up reliability?

What documentation supports treatment escalation in stable but symptomatic disease?

What documentation supports treatment escalation in stable but symptomatic disease?

What documentation supports continued use of ruxolitinib over time?

What documentation supports continued use of ruxolitinib over time?

What clinical context supports ruxolitinib over other topical options?

What clinical context supports ruxolitinib over other topical options?

For patients with vitiligo, what do you focus on in the initial visit before patients even begin treatment with topical therapies?

For patients with vitiligo, what do you focus on in the initial visit before patients even begin treatment with topical therapies?

How do you counsel patients on the timeline of repigmentation with topical therapies for vitiligo?

How do you counsel patients on the timeline of repigmentation with topical therapies for vitiligo?

How do you explain differences in response between facial and nonfacial vitiligo when using topical therapies?

How do you explain differences in response between facial and nonfacial vitiligo when using topical therapies?

How do you counsel patients with vitiligo who are seeing partial improvement but not complete repigmentation?

How do you counsel patients with vitiligo who are seeing partial improvement but not complete repigmentation?

What are the most common adherence challenges you see with topical treatments in vitiligo?

What are the most common adherence challenges you see with topical treatments in vitiligo?

What should clinicians keep in mind when considering treatment for patients with long-standing vitiligo?

What should clinicians keep in mind when considering treatment for patients with long-standing vitiligo?

How do you balance access realities with ideal treatment plans?

How do you balance access realities with ideal treatment plans?

How do you handle denials for FDA-approved therapies?

How do you handle denials for FDA-approved therapies?

How do you handle coverage for patients switching insurance mid-treatment?

How do you handle coverage for patients switching insurance mid-treatment?

What’s your approach when payer criteria conflict with clinical guidelines?

What’s your approach when payer criteria conflict with clinical guidelines?

What helps secure approval for ruxolitinib in patients with limited BSA?

What helps secure approval for ruxolitinib in patients with limited BSA?

How do you position ruxolitinib after partial response to prior therapy?

How do you position ruxolitinib after partial response to prior therapy?

What is the mechanism of action of apremilast?

What is the mechanism of action of apremilast?

In what scenarios do you find apremilast works best alongside other therapies rather than as monotherapy?

In what scenarios do you find apremilast works best alongside other therapies rather than as monotherapy?

What do dermatologists sometimes overlook about apremilast when focusing on newer therapies?

What do dermatologists sometimes overlook about apremilast when focusing on newer therapies?

What counseling strategies have made the biggest difference in helping patients get through the first few weeks on apremilast?

What counseling strategies have made the biggest difference in helping patients get through the first few weeks on apremilast?

How do functionally sensitive areas like hands, feet, or scalp change your threshold for moving beyond topicals?

How do functionally sensitive areas like hands, feet, or scalp change your threshold for moving beyond topicals?

Are we sometimes optimizing for BSA instead of optimizing for the patient’s lived experience?

Are we sometimes optimizing for BSA instead of optimizing for the patient’s lived experience?

What aspects of tapinarof’s AhR-driven mechanism are most clinically meaningful in AD?

What aspects of tapinarof’s AhR-driven mechanism are most clinically meaningful in AD?

Which efficacy outcomes with tapinarof for AD have proven most meaningful in your clinical experience?

Which efficacy outcomes with tapinarof for AD have proven most meaningful in your clinical experience?

Where does tapinarof fit in your current treatment approach for AD?

Where does tapinarof fit in your current treatment approach for AD?

Are there specific body areas or disease patterns in AD where tapinarof has been particularly useful?

Are there specific body areas or disease patterns in AD where tapinarof has been particularly useful?

Do you feel newer nonsteroidal topicals are being used to their full potential in clinical practice?

Do you feel newer nonsteroidal topicals are being used to their full potential in clinical practice?

How do you balance short-term AD control with steroids vs longer-term maintenance with nonsteroidal therapies?

How do you balance short-term AD control with steroids vs longer-term maintenance with nonsteroidal therapies?

When you’re introducing Cordran Tape to someone unfamiliar with it, how do you describe what it is in practical terms, both in terms of its physical form and how it functions on the skin?

When you’re introducing Cordran Tape to someone unfamiliar with it, how do you describe what it is in practical terms, both in terms of its physical form and how it functions on the skin?

Can you walk through how you use the occlusive nature of Cordran Tape in practice, and how it changes your approach compared to standard topical steroids?

Can you walk through how you use the occlusive nature of Cordran Tape in practice, and how it changes your approach compared to standard topical steroids?

Can you walk through a few of the highest-yield clinical scenarios where Cordran Tape really stands out, and what you’ve seen in terms of outcomes?

Can you walk through a few of the highest-yield clinical scenarios where Cordran Tape really stands out, and what you’ve seen in terms of outcomes?

With so many newer topical options available, where do you see Cordran Tape fitting into current treatment approaches?

With so many newer topical options available, where do you see Cordran Tape fitting into current treatment approaches?

In your experience, what are the common reasons traditional topical therapies fall short in certain patients or lesions?

In your experience, what are the common reasons traditional topical therapies fall short in certain patients or lesions?

Are there any older dermatologic therapies or approaches that you feel are underutilized today, and why do you think they’ve been overlooked?

Are there any older dermatologic therapies or approaches that you feel are underutilized today, and why do you think they’ve been overlooked?

What keeps both clinicians and patients stuck in cycles of topical escalation longer than is ideal?

What keeps both clinicians and patients stuck in cycles of topical escalation longer than is ideal?

In patients who have failed or discontinued biologics, when does apremilast reenter consideration?

In patients who have failed or discontinued biologics, when does apremilast reenter consideration?

How do you decide between apremilast and initiating a biologic in a patient who technically qualifies for either?

How do you decide between apremilast and initiating a biologic in a patient who technically qualifies for either?

Are there particular comorbidity profiles where apremilast feels especially appropriate?

Are there particular comorbidity profiles where apremilast feels especially appropriate?

Are there specific patient profiles where apremilast helps bridge the gap between topical therapy and biologics?

Are there specific patient profiles where apremilast helps bridge the gap between topical therapy and biologics?

What lifestyle or occupational factors make oral therapy particularly appealing?

What lifestyle or occupational factors make oral therapy particularly appealing?

How do you document quality-of-life impact in vitiligo or atopic dermatitis?

How do you document quality-of-life impact in vitiligo or atopic dermatitis?

Which clinical metrics carry the most weight with payers?

Which clinical metrics carry the most weight with payers?

How do you justify nonsteroidal therapy after steroid failure?

How do you justify nonsteroidal therapy after steroid failure?

When is a peer-to-peer review worth pursuing?

When is a peer-to-peer review worth pursuing?

How do you document medical necessity for ruxolitinib in mild-to-moderate disease?

How do you document medical necessity for ruxolitinib in mild-to-moderate disease?

When is step therapy inappropriate before ruxolitinib cream?

When is step therapy inappropriate before ruxolitinib cream?

What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence?

What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence?

What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”?

What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”?

Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease?

Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease?

What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments?

What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments?

What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast?

What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast?

Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios?

Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios?

When apremilast first launched, how was it positioned, and what do we understand differently now?

When apremilast first launched, how was it positioned, and what do we understand differently now?

How do you frame quality-of-life impact when requesting coverage for ruxolitinib?

How do you frame quality-of-life impact when requesting coverage for ruxolitinib?

When do bridge programs make the most clinical sense for patients?

When do bridge programs make the most clinical sense for patients?

How do you document treatment goals when requesting newer therapies?

How do you document treatment goals when requesting newer therapies?

How do you document medical necessity when disease severity seems borderline?

How do you document medical necessity when disease severity seems borderline?

What clinical language resonates most with payers during prior authorization review?

What clinical language resonates most with payers during prior authorization review?

How do you document body surface area or lesion burden for ruxolitinib coverage decisions?

How do you document body surface area or lesion burden for ruxolitinib coverage decisions?

When might ruxolitinib cream be appropriate earlier in the treatment pathway?

When might ruxolitinib cream be appropriate earlier in the treatment pathway?

What is the single most meaningful management decision that becomes clearer after genomic testing?

What is the single most meaningful management decision that becomes clearer after genomic testing?

Where do you think clinicians are most likely to misinterpret or overextend genomic test results?

Where do you think clinicians are most likely to misinterpret or overextend genomic test results?

What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx?

What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx?

Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively?

Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively?

What can AdvanceAD-TX tell you that clinical phenotype alone does not?

What can AdvanceAD-TX tell you that clinical phenotype alone does not?

How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases?

How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases?

Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice?

Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice?

Has the DecisionDx Melanoma test influenced your imaging threshold in select patients?

Has the DecisionDx Melanoma test influenced your imaging threshold in select patients?

How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align?

How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align?

How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology?

How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology?

Have there been cases where DecisionDx-SCC reclassified a tumor you initially considered low or intermediate risk? How did that change management?

Have there been cases where DecisionDx-SCC reclassified a tumor you initially considered low or intermediate risk? How did that change management?

Has MyPath meaningfully reduced the number of wide excisions you perform for ambiguous lesions?

Has MyPath meaningfully reduced the number of wide excisions you perform for ambiguous lesions?

In the evaluation of melanocytic lesions suspicious for melanoma, how do you decide when diagnostic ambiguity is acceptable versus when additional molecular data is necessary?

In the evaluation of melanocytic lesions suspicious for melanoma, how do you decide when diagnostic ambiguity is acceptable versus when additional molecular data is necessary?

What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?

What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?

How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?

How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?

When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?

When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?

In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?

In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?

How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?

How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?

In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?

In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?

What clinical details make an appeal letter more persuasive?

What clinical details make an appeal letter more persuasive?

What supporting materials help overturn a denial?

What supporting materials help overturn a denial?

When do you escalate from prior auth to formal appeal?

When do you escalate from prior auth to formal appeal?

What’s one documentation habit that consistently improves approvals?

What’s one documentation habit that consistently improves approvals?

How do you document steroid failure before prescribing ruxolitinib cream?

How do you document steroid failure before prescribing ruxolitinib cream?

What helps secure coverage for ruxolitinib in step therapy plans?

What helps secure coverage for ruxolitinib in step therapy plans?

What documentation details helps support approval for ruxolitinib cream?

What documentation details helps support approval for ruxolitinib cream?

CME & Education About Us

Loading profile...

Conditions & Treatments
Learn from the Experts
Support Your Practice
Conferences & Highlights
CME Activities
Educational Resources
Community Resources
Our Expert Network

The leading solutions platform for dermatology professionals to elevate patient care.

Helpful Links

Terms of Service

Editorial & Medical Review Policy

Privacy Policy

Cookie Policy

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2026 dermsquared | All Rights Reserved